GSK nears end of OTC bidding process

GlaxoSmithKline ($GSK) is weighing final offers for the portfolio of over-the-counter products it has put on the block, sources tell Reuters. The two front-runners in the second round of bidding are Bain Capital and a partnership between Blackstone and Prestige Brands, the sources said. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.